203 related articles for article (PubMed ID: 17202312)
21. Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1.
Valeyrie-Allanore L; Ismaïli N; Bastuji-Garin S; Zeller J; Wechsler J; Revuz J; Wolkenstein P
Br J Dermatol; 2005 Jul; 153(1):79-82. PubMed ID: 16029330
[TBL] [Abstract][Full Text] [Related]
22. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
23. Adhesion molecule L1 is down-regulated in malignant peripheral nerve sheath tumors versus benign neurofibromatosis type 1-associated tumors.
Blessmann M; Gröbe A; Quaas A; Kaifi JT; Mistakidis G; Bernreuther C; Sauter G; Gros S; Rawnaq T; Friedrich R; Mautner VF; Smeets R; Heiland M; Schachner M; Izbicki JR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Feb; 113(2):239-44. PubMed ID: 22677742
[TBL] [Abstract][Full Text] [Related]
24. Brachial plexopathy due to malignant peripheral nerve sheath tumor in neurofibromatosis type 1: case report and subject review.
Pacelli J; Whitaker CH
Muscle Nerve; 2006 May; 33(5):697-700. PubMed ID: 16323217
[TBL] [Abstract][Full Text] [Related]
25. CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene.
Sherman L; Jacoby LB; Lampe J; Pelton P; Aguzzi A; Herrlich P; Ponta H
Cancer Res; 1997 Nov; 57(21):4889-97. PubMed ID: 9354454
[TBL] [Abstract][Full Text] [Related]
26. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells.
Fishbein L; Eady B; Sanek N; Muir D; Wallace MR
Cancer Genet Cytogenet; 2005 Mar; 157(2):181-6. PubMed ID: 15721644
[TBL] [Abstract][Full Text] [Related]
27. NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.
Pros E; Larriba S; López E; Ravella A; Gili ML; Kruyer H; Valls J; Serra E; Lázaro C
Hum Mutat; 2006 Nov; 27(11):1104-14. PubMed ID: 16937374
[TBL] [Abstract][Full Text] [Related]
28. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C
Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459
[TBL] [Abstract][Full Text] [Related]
29. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
30. Aberrant expression of tenascin-c and neuronatin in malignant peripheral nerve sheath tumors.
Dugu L; Hayashida S; Nakahara T; Xie L; Iwashita Y; Liu X; Uchi H; Tateuchi S; Takahara M; Oda Y; Moroi Y; Furue M
Eur J Dermatol; 2010; 20(5):580-4. PubMed ID: 20610366
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence in situ hybridization analysis of allelic losses involving the long arm of chromosome 17 in NF1-associated neurofibromas.
De Luca A; Bernardini L; Ceccarini C; Sinibaldi L; Novelli A; Giustini S; Daniele I; Calvieri S; Mingarelli R
Cancer Genet Cytogenet; 2004 Apr; 150(2):168-72. PubMed ID: 15066327
[TBL] [Abstract][Full Text] [Related]
32. An induction gene trap screen in neural stem cells reveals an instructive function of the niche and identifies the splicing regulator sam68 as a tenascin-C-regulated target gene.
Moritz S; Lehmann S; Faissner A; von Holst A
Stem Cells; 2008 Sep; 26(9):2321-31. PubMed ID: 18617690
[TBL] [Abstract][Full Text] [Related]
33. A patient severely affected by spinal neurofibromas carries a recurrent splice site mutation in the NF1 gene.
Wimmer K; Mühlbauer M; Eckart M; Callens T; Rehder H; Birkner T; Leroy JG; Fonatsch C; Messiaen L
Eur J Hum Genet; 2002 May; 10(5):334-8. PubMed ID: 12082509
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
35. Clinical, pathologic, and genetic features of massive soft tissue neurofibromas in a Sicilian patient.
Bongiorno MR; Cefalù AB; Aricò M; Averna M
Dermatol Ther; 2008; 21 Suppl 3():S21-5. PubMed ID: 19076627
[TBL] [Abstract][Full Text] [Related]
36. Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals.
Mantripragada KK; Caley M; Stephens P; Jones CJ; Kluwe L; Guha A; Mautner V; Upadhyaya M
Genes Chromosomes Cancer; 2008 Mar; 47(3):238-46. PubMed ID: 18069666
[TBL] [Abstract][Full Text] [Related]
37. Malignant peripheral nerve sheath tumour of the cervical vagus nerve in a neurofibromatosis type 1 patient.
Molina AR; Brasch H; Tan ST
J Plast Reconstr Aesthet Surg; 2006; 59(12):1458-62. PubMed ID: 17113542
[TBL] [Abstract][Full Text] [Related]
38. Is the distribution of dermal neurofibromas in neurofibromatosis type 1 (NF1) related to the pattern of the skin surface temperature?
Kaufmann D; Tinschert S; Algermissen B
Eur J Dermatol; 2001; 11(6):521-6. PubMed ID: 11701400
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic delay of NF1 in hemifacial hypertrophy due to plexiform neurofibromas.
Overdiek A; Feifel H; Schaper J; Mayatepek E; Rosenbaum T
Brain Dev; 2006 Jun; 28(5):275-80. PubMed ID: 16481142
[TBL] [Abstract][Full Text] [Related]
40. A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1.
Garza R; Hudson RA; McMahan CA; Walter CA; Vogel KS
Mutat Res; 2007 Feb; 615(1-2):98-110. PubMed ID: 17208258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
